Device brand name · Biopsy instrument
Bard Max-Core Disposable Biopsy Instrument: medical device reports filed with FDA
2,335 reports name it, 2020–2021. Manufacturer given most often on reports: Bard Peripheral Vascular. Product code KNW.
- 2,335
- device reports naming the brand
- 0% of all MAUDE reports · about 374 a year
- 0
- reports, 12 months to August 2026
- 0 in the 12 months before
- 99.8%
- classified as malfunction
- 90.5% across the product code
- 0%
- classified as death, as reported
- 0 reports · not verified by FDA
FDA's MAUDE database holds 2,335 reports that name the brand "Bard Max-Core Disposable Biopsy Instrument" (biopsy instrument), received between April 2020 and September 2021; the manufacturer given most often on reports is Bard Peripheral Vascular. Spellings of one product vary from report to report.
0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are malfunction (99.8%) and injury (0.2%); across all instrument, biopsy reports (product code KNW) death is recorded in 0.1% and malfunction in 90.5%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are failure to fire (83.3%), failure to obtain sample (14.8%) and self-activation or keying (1.5%). The patient problems coded most often are no patient involvement, hemorrhage/blood loss/bleeding and hematuria. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 24,120 reports carrying product code KNW. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Failure to fire | 1,945 | 83.3% | 30.2% |
| Failure to obtain sample | 345 | 14.8% | 11% |
| Self-activation or keying | 34 | 1.5% | 8.2% |
| Failure to prime | 12 | 0.5% | 3.7% |
| Difficult to removethe device was hard to remove | 9 | 0.4% | 3.5% |
| Firing problem | 8 | 0.3% | 0.4% |
| Material twisted/bent | 7 | 0.3% | 1.5% |
| Device contamination with chemical or other material | 6 | 0.3% | 1.5% |
| Component misassembled | 1 | 0% | 0.1% |
| Fracturea broken bone | 1 | 0% | 0.3% |
| Tear, rip or hole in device packaging | 1 | 0% | 0.9% |
| Unsealed device packaging | 1 | 0% | 0.3% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| No patient involvement | 214 | 9.2% |
| Hemorrhage/blood loss/bleeding | 3 | 0.1% |
| Hematuria | 1 | 0% |
| Painpain, site not specified | 1 | 0% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Bard Max-Core Disposable Biopsy Instrument | Product code KNW | All MAUDE reports |
|---|---|---|---|
| Reports | 2,335 | 24,120 | 26,136,888 |
| Share of that pool | — | 9.7% | 0% |
| Classified as death, per 1,000 reports | 0 | 1 | 9 |
| Classified as injury | 0.2% | 8.3% | 36.2% |
| Classified as malfunction | 99.8% | 90.5% | 62.3% |
| Filed by the manufacturer | 100% | 94.6% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code KNW
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| EnCor Biopsy Probe | 5,264 | 15 | 0% |
| Maxcore | 4,025 | 1,890 | 0% |
| Bard Max-Core Disposable Core Biopsy Instrument | 2,657 | 0 | 0% |
| Mtome St Holster/Cables | 495 | 0 | 0% |
| Mammotome Control Module With Smartvac - 120v | 339 | 0 | 0% |
| Brevera Breast Biopsy System | 319 | 69 | 0% |
| Monopty Disposable Core Biopsy Instrument | 288 | 0 | 0% |
| Marquee | 233 | 46 | 0% |
| Asap Biopsy System | 213 | 0 | 0.5% |
| Max-Core Disposable Core Biopsy Instrument | 205 | 0 | 0% |
| Mammotome Hardware Holster | 173 | 0 | 0% |
| Achieve | 164 | 125 | 0% |
| Mammotome Control Modules | 157 | 0 | 0% |
| Radial Jaw 3 Biopsy Forceps | 302 | 0 | 0% |
| Superdimension | 227 | 5 | 7% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Bard Max-Core Disposable Biopsy Instrument reports
How many FDA reports name Bard Max-Core Disposable Biopsy Instrument?
2,335 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 0 in the latest 12 months.
What kinds of events are reported?
malfunction (99.8%) and injury (0.2%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
failure to fire (83.3%), failure to obtain sample (14.8%), self-activation or keying (1.5%), failure to prime (0.5%) and difficult to remove (0.4%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Bard Max-Core Disposable Biopsy Instrument was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.